Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer

被引：0
|
作者：
Hirotoshi Ishiwatari
Tsuyoshi Hayashi
Makoto Yoshida
Michihiro Ono
Tsutomu Sato
Koji Miyanishi
Yasushi Sato
Rishu Takimoto
Masayoshi Kobune
Junji Kato
机构：
[1] Sapporo Medical University School of Medicine,Department of Medical Oncology and Hematology
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Biliary tract cancer; Hepatic arterial infusion; Chemotherapy; S-1; Gemcitabine; Neutropenia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：805 / 812
页数：7
相关论文
共 50 条
  • [31] Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study
    Takahara, Naminatsu
    Isayama, Hiroyuki
    Nakai, Yousuke
    Sasaki, Takashi
    Ishigaki, Kazunaga
    Saito, Kei
    Akiyama, Dai
    Uchino, Rie
    Mizuno, Suguru
    Yagioka, Hiroshi
    Kogure, Hirofumi
    Togawa, Osamu
    Matsubara, Saburo
    Ito, Yukiko
    Toda, Nobuo
    Tada, Minoru
    Koike, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (03) : 269 - 276
  • [32] A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer
    Masashi Kanai
    Kenichi Yoshimura
    Takehiko Tsumura
    Masanori Asada
    Chihiro Suzuki
    Miyuki Niimi
    Shigemi Matsumoto
    Takafumi Nishimura
    Takashi Nitta
    Kentaro Yasuchika
    Kojiro Taura
    Yukiko Mori
    Akihiko Hamada
    Naoya Inoue
    Shinsuke Tada
    Kazuhiro Yanagihara
    Shujiro Yazumi
    Yukio Osaki
    Tsutomu Chiba
    Iwao Ikai
    Masanori Fukushima
    Shinji Uemoto
    Etsuro Hatano
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1429 - 1434
  • [33] A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer
    Kanai, Masashi
    Yoshimura, Kenichi
    Tsumura, Takehiko
    Asada, Masanori
    Suzuki, Chihiro
    Niimi, Miyuki
    Matsumoto, Shigemi
    Nishimura, Takafumi
    Nitta, Takashi
    Yasuchika, Kentaro
    Taura, Kojiro
    Mori, Yukiko
    Hamada, Akihiko
    Inoue, Naoya
    Tada, Shinsuke
    Yanagihara, Kazuhiro
    Yazumi, Shujiro
    Osaki, Yukio
    Chiba, Tsutomu
    Ikai, Iwao
    Fukushima, Masanori
    Uemoto, Shinji
    Hatano, Etsuro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1429 - 1434
  • [34] Arterial infusion of cisplatin plus S-1 against unresectable intrahepatic cholangiocarcinoma
    Higaki, Tokio
    Aramaki, Osamu
    Moriguchi, Masamichi
    Nakayama, Hisashi
    Midorikawa, Yutaka
    Takayama, Tadatoshi
    BIOSCIENCE TRENDS, 2018, 12 (01) : 73 - 78
  • [35] Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
    Inoue, Hiroto
    Todaka, Akiko
    Yamazaki, Kentaro
    Fushiki, Kunihiro
    Shirasu, Hiromichi
    Kawakami, Takeshi
    Tsushima, Takahiro
    Hamauchi, Satoshi
    Yokota, Tomoya
    Machida, Nozomu
    Fukutomi, Akira
    Onozawa, Yusuke
    Andoh, Akira
    Yasui, Hirofumi
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1399 - 1404
  • [36] A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer
    Takahara, Naminatsu
    Isayama, Hiroyuki
    Nakai, Yousuke
    Sasaki, Takashi
    Saito, Kei
    Sato, Tatsuya
    Hakuta, Ryunosuke
    Ishigaki, Kazunaga
    Saito, Tomotaka
    Hamada, Tsuyoshi
    Mizuno, Suguru
    Kogure, Hirofumi
    Tada, Minoru
    Koike, Kazuhiko
    JOURNAL OF CHEMOTHERAPY, 2019, 31 (05) : 284 - 289
  • [37] Evaluation of Prognostic Factors in Patients with Relapse and Unresectable Biliary Tract Cancer, Treated with S-1 after Failure of Gemcitabine
    Nakai, Masato
    Kikkawa, Akiyoshi
    Funahara, Hiroko
    Matsumoto, Shunji
    Hiraki, Koichi
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2022, 142 (09): : 1021 - 1029
  • [38] Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial
    Li, Hao
    Zhang, Zheng-Yun
    Zhou, Zun-Qiang
    Guan, Jiao
    Tong, Da-Nian
    Zhou, Guang-Wen
    ONCOTARGET, 2016, 7 (18) : 26888 - 26897
  • [39] Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer
    Kaira, Kyoichi
    Sunaga, Noriaki
    Yanagitani, Noriko
    Aoki, Haruka
    Kawata, Tadayoshi
    Utsugi, Mitsuyoshi
    Shimizu, Yasuo
    Shimizu, Kimihiro
    Hisada, Takeshi
    Ishizuka, Tamotsu
    Mori, Masatomo
    ANTI-CANCER DRUGS, 2008, 19 (03) : 289 - 294
  • [40] Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial)
    Sai, Satoshi
    Toyoda, Masanori
    Tobimatsu, Kazutoshi
    Satake, Hironaga
    Yasui, Hisateru
    Kimbara, Shiro
    Koyama, Taiji
    Fujishima, Yoshimi
    Imamura, Yoshinori
    Funakoshi, Yohei
    Kiyota, Naomi
    Toyama, Hirochika
    Kodama, Yuzo
    Minami, Hironobu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (01) : 65 - 71
12345